Johnson & Johnson's investigational co-antibody therapy JNJ-4804 demonstrated higher clinical remission and endoscopic response rates compared to golimumab and guselkumab in patients with moderately to severely active ulcerative colitis and Crohn's disease who failed two or more systemic therapies. Data from Phase 2b DUET studies showed meaningful improvements at Week 48, especially in highly refractory patients, addressing a critical unmet need in inflammatory bowel disease treatment. JNJ-4804 targets both IL-23 and TNF pathways, offering a synergistic approach. Based on these results, Johnson & Johnson plans to initiate Phase 3 trials for both conditions.
Five established companies—Johnson & Johnson, PepsiCo, Coca-Cola, Exxon Mobil, and Kimberly-Clark—have declared new dividends backed by decades of consistent payout increases. Each company recently reported strong earnings or raised guidance, signali...
Johnson & Johnson's stock reached $270.24, close to its 52-week high of $276.47, following raised full-year guidance and FDA approval of a new robotic surgical system. The company shows strong growth in oncology and immunology, with key products like...
Jim Cramer highlighted a market rotation away from tech and data center stocks toward enterprise software and pharmaceuticals, driven by political opposition to data center construction and bond market volatility. Software companies like ServiceNow, ...
With the 10-Year Treasury yield at 4.74%, dividend stocks must offer durable income. Dividend Aristocrats, companies with 25+ years of dividend increases, remain reliable for retirement income. Coca-Cola, Procter & Gamble, Johnson & Johnson, PepsiCo,...
The FDA has approved IMAAVY (nipocalimab-aahu) for treating warm autoimmune hemolytic anemia (wAIHA) in patients aged 12 and older, marking the first therapy specifically proven safe and effective for this rare, life-threatening disease. IMAAVY works...
